Renal Effects of Molecular Targeted Therapies in Oncology. A review by the Cancer and the Kidney International Network (C-KIN)
Cet article passe en revue les travaux récents ayant mis en évidence des effets indésirables sur la fonction rénale induits par des thérapies ciblées chez des patients atteints d'un cancer
A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic including, targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to VEGF/VEGFR, EGFR, HER2, BRAF, ALK, PD1/PDL1, RANKL, mTOR. The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.